T he identification of a gain-of-function mutation in the Janus kinase 2 gene, named JAK2 (V617F), opened a new era in the understanding of Philadelphia-negative myeloproliferative neoplasms, 1, 2 including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). These entities share some clinical features such as a high risk of developing thrombosis, 3 evolution into secondary myelofibrosis (for PV and ET) and transformation into leukemia. 4 The most intriguing question that arose after the discovery of the mutation is how a single mutation might give rise to at least three different diseases. This question remains unanswered, but clinical, biological and pathological data have led to three potential hypotheses. One, called the gene-dosage hypothesis, postulates a correlation between disease phenotype and the proportion of JAK2 (V617F) mutant alleles introducing the concept of allele burden, that is, the ratio between mutant and wild type JAK2 in hematopoietic cells. Experiments on transgenic mice expressing variable levels of JAK2 (V617F) support this hypothesis. 5 In fact low levels of JAK2 (V617F) load induce an ET-like phenotype dominated by thrombocytosis, whereas higher levels of mutant alleles lead to a PV-like phenotype. A critical role of gene dosage effect is also indicated by studies on erythroid colonies. Homozygous JAK2 (V617F) erythroid colonies are present in most patients with PV, but occur rarely in those with ET. 6 A second hypothesis advocates the existence of a pre-JAK2 phase in which additional somatic mutations or inherited predisposing alleles establish clonal hematopoiesis before the acquisition of JAK2 (V617F). Thus, mutations other than JAK2 may determine disease phenotype directly or by co-operating with JAK2 mutations. Analysis of the X-chromosome inactivation pattern of clonality in familial cases of myeloproliferative neoplasm 7 has provided support for this hypothesis.
Finally, host genetic factors may contribute to phenotypic diversity among myeloproliferative neoplasms. This was documented in patients with PV and ET tested for genetic variation within JAK2, MPL, EPOR, and GCSFR genes using single nucleotide polymorphisms. 8 In addition, strain-specific differences in phenotype have been observed in mice transplanted with JAK2 (V617F) transfected cells: Balb/c mice demonstrated markedly higher leukocyte counts, splenomegaly, and bone marrow reticulin fibrosis compared with C57Bl/6 mice. 9 Likely, the three hypotheses, although explanatory individually, are not mutually exclusive. This is true for the patient whose clinical history is illustrated in Figure  1 . This is the case of a 23-year old female with familial myeloproliferative neoplasm, whose father and uncle had ET (Figure 1a) . The young girl, after an initial diagnosis of ET, developed PV with a JAK2 (V617F) allele burden of 24.8% and clonal hematopoiesis, demonstrated through X-chromosome inactivation patterns ( Figure 1b) . She had erythrocytosis, thrombocytosis and did not display mobilization of CD34-positive cells. A few years later she developed myelofibrosis with an increase of the mutant allele burden to 63.3%, and an increase of circulating CD34-positive cells (Figure 1c ). This case is in favor of a critical gene-dosage effect of JAK2 (V617F) on disease evolution, as the increase of allele burden corresponded with the myelofibrotic transformation. However, the case also supports the role of additional pre-existing mutations inherited in a genetically predisposed individual. In fact, this is a case of familial myeloproliferative neoplasm and a low allele burden exists within a milieu of clonal hematopoiesis.
The distribution of the JAK2 (V617F) mutation among PV, ET and PMF seems heterogeneous, as almost all patients with PV and with post-PV myelofibrosis and about half of those with ET and PMF carry the mutation. There is now a growing interest in JAK2 (V617F) allele burden and its potential influence on disease phenotype, disease complications and evolution. The starting point for studying the clinical significance of allele burden is its correct assessment by quantitative assays. In this regard, the paper by Lippert et al. in this issue of the journal is of major interest. 10 Lippert et al. 14 but not in others. 15 In this regard, it is interesting to note that patients with PV that has evolved into myelofibrosis have the highest allele burden and almost all have anemia. 16 Thrombopoiesis is particularly stimulated by low allele burden, as an inverse relationship between allele burden and platelet count has been reported. This is in keeping with the low level of mutant alleles found in ET patients, whose clinical phenotype is dominated by thrombocytosis. 12, 13 Finally, all studies reported a correlation between allele burden and spleen size, confirming the role of mutant allele burden in stimulating myelopoiesis. Allele burden correlates linearly with leukocyte count and spleen size also in patients with ET and PMF. 13, [17] [18] [19] The bottom of Figure 2 illustrates the tentative correlations between allele burden and leukocyte count, hemoglobin level and platelet count. Disease-related complications and evolution basically include thrombosis, myelofibro- There is considerable debate on these latter potential risk factors, but a broad consensus has not yet been reached. The mutation may affect leukocyte count, leukocyte and platelet activation, 11 platelet-leukocyte interactions, as well as plasma hypercoagulation factors 20 and, in turn, these activated factors may potentially influence thrombosis. Results from clinical studies aimed at defining the correlation between the mutation or its allele burden and the occurrence of vascular complications ae conflicting. 21 The knowledge on this field seems premature and needs further validation: this accounts for the question marks we use in the top panel of Figure 2 . Myelofibrosis is considered a bona fide natural evolution in both PV and ET. We reported that patients with myeloproliferative neoplasms who carry the JAK2 (V617F) mutation have a higher risk of post-PV myelofibrosis than those who do not carry the mutation. 1 Two studies applying a semi-quantitative assay found that transformation into post-PV myelofibrosis occurred more frequently in homozygous PV patients than in heterozygous ones. 22, 23 In ET the much less frequent occurrence of myelofibrosis and the low allele burden did not allow any correlation to be found. The relationship between mutant allele burden and the occurrence of leukemia in PV and ET has not been defined so far. Concerning myelofibrosis, one study supports a critical role of allele burden in the progression of the disease, as the majority of patients with leukemia were homozygous for the mutation. 19 However, another study reported opposite results, as the majority of patients with leukemia had a low allele burden or wild type JAK2. 18 This suggests that a low allele burden may be overwhelmed by a more dominant JAK2 (V617F)-negative clone with a higher propensity to leukemic transformation.
In conclusion, current knowledge indicates that allele burden has a role in clinical phenotype and disease-evolution and suggests a potential relationship with vascular complications. Although these correlations have been consistently observed in clinical practice, it is premature to consider allele burden as a prognostic parameter to be applied for therapeutic interventions. In our opinion, we must now wait for the next lesson, which will come from the new agents with a potential to switch-off JAK2, named JAK2-inhibitors. Will these compounds be able to reduce allele burden without toxicity? Will the current knowledge be validated? © F e r r a t a S t o r t i F o u n d a t i o n T en years ago therapy of newly-diagnosed acute myeloid leukemia (AML) was largely invariant. Patients received daunorubicin or idarubicin for 3 days and cytarabine (ara-C) at a dose of 100 mg/m 2 daily for 7 days as a continuous infusion, a regimen commonly known as "3+7". Nowadays, however, guidelines, such as those in the paper by Morra et al., 1 recommend that many older patients be given investigational therapies at diagnosis. This change reflects the greater availability of new treatments, often thought to be targeted to specific abnormalities in AML blasts. The advent of a broader range of investigational therapies and increased knowledge about the molecular biology of AML has raised several questions, which I address here: (i) which patients are candidates for investigational therapy? (ii) should cytogenetic and molecular information be used to plan initial therapy? (iii) what is the current role of allogeneic hematopoietic stem cell transplant (HSCT)? (iv) regarding targeted therapy -are responses less than a complete response worthwhile, how long should therapy be continued before failure is declared, should combinations with chemotherapy or other targeted agents be explored sooner than is currently the case, and should these agents be reserved for a specific population or used more broadly? and (v) given the increasing recognition of the biological and prognostic heterogene-
